Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

Bristol Myers Squibb gets earlier PDUFA date for subcutaneous Opdivo
Monoclonal antibody, cancer - Read more

THE GOOD
Business Development

Alloy Therapeutics licenses antibody discovery tech to Eli Lilly 
Antibody, drug discovery - Read more

THE GOOD
Clinical Trials

Larimar Therapeutics escapes FDA clinical hold after Ph2 review
Fusion protein, Friedreich’s ataxia - Read more 

GSK puffs out chest on positive Ph3 asthma trial data
Monoclonal antibody, severe asthma - Read more

J&J Medtech division touts positive clinical data
Medical device, pulsed field ablation, atrial fibrillation - Read more

Eli Lilly’s mirikizumab moves beyond ulcerative colitis, posts positive Ph3 Crohn’s disease data
Monoclonal antibody, Crohn’s disease - Read more

THE GOOD
Fundraises

YGION Biomedical €15m ($16M) Series A
Neoantigen cancer vaccines - Read more

Oxford Endovascular £8M ($14M) Series A+
Medical device, intracranial aneurysms - Read more

LabGenius £35m ($45M) Series B
Machine learning, multispecific antibody, drug discovery - Read more

Pheon Therapeutics $120B Series B
Antibody-drug conjugate, cancer - Read more

AltruBio $225M Series B
Antibody, ulcerative colitis - Read more

THE GOOD
Partnerships

Komodo Health’s specialty data partnerships
SaaS, healthcare data analytics - Read more

Eli Lilly signs radiopharma collab with Aktis Oncology
$60M upfront, $1.1b biobucks and royalties
Radiopharma, cancer - Read more

Astellas dives into automated cell therapy game with Yaskawa Electric Corporation
Cell therapy, automated manufacturing - Read more

Sanofi, Formation Bio, and OpenAI collab on AI-powered drug discovery
AI, drug discovery, software development - Read more

BioNTech, Medigene extend drug discovery and development collab
T cell receptor, cancer - Read more

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

Use discount code WELCOMETOSALESTLDR for $100 off!

THE GOOD
Patient Access

University of Oxford, Novavax-developed malaria shot finally hits Africa thanks to Serum Institute of India
Vaccine, malaria - Read more

THE GOOD
Politics & Policy

NIH proposes biopharma transparency on drugs developed using tax-payer dollars
Drug development, public funding - Read more [Paywall]

Senate Judiciary Committee shows bipartisan support for pharma patent reform
Drug patents - Read more [Paywall]

THE GOOD
Product Launches

Hims & Hers offers compounded obesity meds; stock pops
GLP-1, obesity, consumer health - Read more

…though coincidentally, Australia is moving to ban compounded weight-loss drugs - Read more

Parallel Bio launches animal model alternative for drug development
Animal models, “Clinical Trial in a Dish” - Read more

THE GOOD
Research

Catalogue of Somatic Mutations in Cancer (COSMIC) release new depository
Research resource, gene variants, cancer - Read more

Independent research study says Phenomix Sciences genetic test predicts who will lose the most weight on semaglutide
Semaglutide, GLP-1, obesity - Read more

THE GOOD
Strategic Plans

AstraZeneca aims for staggering $80B in sales by 2030
Drug development, cancer - Read more

…and China plays a big part into AstraZeneca’s $80B ambitions
R&D, cell therapy - Read more

…and last one here for AstraZeneca - they’re focusing on “difficult-to-copy” drugs to secure that $80B bag
Generics, biosimilars, drug patents - Read more [Paywall]

Novo Nordisk is planning beyond weight loss
Liver disease, kidney disease, Alzheimer’s - Read more [Paywall]

THE BAD
Layoffs

Exscientia cut 25% of their staff
AI, drug development, inflammation - Read more

Lyra Therapeutics obliterates workforce with 75% reduction
Medical implant, chronic rhinosinusitis, small molecule - Read more

THE UGLY
Lawsuits

Lawsuit alleges GSK knew about Zantac’s cancer risk for decades
Cancer, small molecule, heartburn - Read more

THE UGLY
Politics & Policy

Lawmaker draws target on Pfizer in pharmaceutical tax probe
Corporate taxes - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 150+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.